drugset
Drugs / Realgar-Indigo Naturalis Formula
last change Jun 2025 re-read 2 minutes ago

Realgar-Indigo Naturalis Formula

also known as RIF

Traditional medicine (herbal / TCM)

Developed for
acute promyelocytic leukemia · acute myeloid leukemia · childhood acute lymphoblastic leukemia · hepatocellular carcinoma · rhabdomyosarcoma
Investigated by
First Affiliated Hospital Xi'an Jiaotong University · First Affiliated Hospital of Guangxi Medical University · First Affiliated Hospital of Shantou University Medical College · First Affiliated Hospital, Sun Yat-Sen University · Guangzhou First People's Hospital · Hainan People's Hospital
+12 more · Huizhou Municipal Central Hospital · LiuZhou People's Hospital · Second Xiangya Hospital of Central South University · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tang-Du Hospital · The First Affiliated Hospital of Guangzhou Medical University · Third Affiliated Hospital, Sun Yat-Sen University · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Zhejiang University · Zhongshan Bo Ai Hospital · Zhongshan People's Hospital, Guangdong, China · Zhujiang Hospital

Trials 6 · a red edge is where a trial was stopped

today NCT07503730 · Ph 3 NCT05708391 · Ph 2 NCT05682131 · Ph 4 NCT04232722 · Ph 2 NCT05297123 · Ph 1 NCT02899169 · Ph 3
201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05297123 Feb 2019 → Dec 2023 acute myeloid leukemia First Affiliated Hospital Xi'an Jiaotong University Unknown No outcome recorded
Phase 22 trials
Phase 2 NCT05708391 Jan 2023 → Mar 2024 rhabdomyosarcoma Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Unknown No outcome recorded
Phase 2 NCT04232722 Jan 2020 → Dec 2021 hepatocellular carcinoma Zhejiang University Unknown No outcome recorded
Phase 32 trials
Phase 3 NCT07503730 Jun 2025 → Jun 2028 expected acute promyelocytic leukemia First Affiliated Hospital Xi'an Jiaotong University Recruiting No outcome recorded
Phase 3 NCT02899169 Sep 2016 → Sep 2022 acute promyelocytic leukemia First Affiliated Hospital Xi'an Jiaotong University Unknown No outcome recorded
Phase 41 trial
Phase 4 NCT05682131 Sep 2022 → Sep 2027 expected childhood acute lymphoblastic leukemia Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as Realgar-Indigo Naturalis Formula “realgar-indigo naturalis formula preparation at 60mg/kg tid p.o” NCT04232722 ↗
5

“Realgar-Indigo Naturalis Formula, oral, for 1 week (Days 0-7).” NCT07503730 ↗

NCT05297123 ↗

NCT05682131 ↗

NCT02899169 ↗

NCT05708391 ↗
Known as RIF “Radiotherapy Combined With Realgar-Indigo Naturalis Formula (RIF) in the Treatment of Rhabdomyosarcoma(RMS) in Children” NCT05708391 ↗
2

“Realgar-Indigo Naturalis Formula (RIF) is an oral arsenic-containing Chinese patent medicine.” NCT07503730 ↗

“Realgar-Indigo Naturalis Formula (RIF)” NCT04232722 ↗
Modality Traditional medicine (herbal / TCM) “Realgar Indigo naturalis formula is a compound traditional Chinese medicine preparation developed in China.” NCT05682131 ↗
Route Oral “oral RIF” NCT02899169 ↗